drug

ATX-295

Phase 2updated 3mo ago

by Accent Therapeutics Inc

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ATX-295

phase1First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancerrecruitingn=90

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 23m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

ATX-295

Phase 2updated 3mo ago

by Accent Therapeutics Inc

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ATX-295

phase1First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancerrecruitingn=90

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 23m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ATX-295

all catalysts(0)

Trials studying ATX-295

News(0)

Report a data issue

comments(0)

ATX-295

all catalysts(0)

Trials studying ATX-295

News(0)

Report a data issue

comments(0)